Zacks Research Issues Negative Estimate for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research reduced their Q2 2025 EPS estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Thursday, March 20th. Zacks Research analyst R. Department now anticipates that the biotechnology company will earn $0.01 per share for the quarter, down from their previous estimate of $0.04. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.24 EPS and FY2027 earnings at $0.36 EPS.

Several other equities research analysts have also commented on IRWD. JMP Securities decreased their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Craig Hallum reduced their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.60.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock opened at $1.49 on Monday. Ironwood Pharmaceuticals has a fifty-two week low of $1.34 and a fifty-two week high of $9.01. The firm has a market capitalization of $238.44 million, a price-to-earnings ratio of -49.67 and a beta of 0.37. The stock’s fifty day moving average is $2.22 and its two-hundred day moving average is $3.46.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). The firm had revenue of $90.55 million for the quarter, compared to analysts’ expectations of $93.85 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by company insiders.

Institutional Trading of Ironwood Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its position in shares of Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after buying an additional 450,949 shares during the period. State Street Corp lifted its position in Ironwood Pharmaceuticals by 7.3% during the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after acquiring an additional 677,024 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Ironwood Pharmaceuticals by 5.5% in the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock worth $40,163,000 after acquiring an additional 469,043 shares during the period. Geode Capital Management LLC grew its position in Ironwood Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock valued at $14,652,000 after acquiring an additional 13,028 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Ironwood Pharmaceuticals by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock valued at $8,786,000 after acquiring an additional 78,969 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.